[Studies on the effect of the alpha-receptor stimulant, gutron, in the orthostatic syndrome (author's transl)].
20 patients, aged 17 to 35 years, with static, labile circulatory disturbances were selected on the basis of an orthostatic test for inclusion in a double-blind trial of Gutron, an alpha-receptor stimulatory drug. The duration of the trial was third weeks and 5 mg Gutron twice daily or placebo was randomly administered in the second week. Venous capacity and circulatory performance under orthostatic conditions (upright) and also under ergometer stress were evaluated. Changes in general well-being objectified by means of a self-assessment scale. Gutron achieved a lowering of the decrease in venous capacity during orthostatis, whereby the systolic blood pressure was raised and the diastolic blood pressure decreased. These features, in conjunction with a broadening of the amplitude and a decrease in pulse rate, point to an essential economisation of the circulation. The results were generally similar during ergometer work. The improvement in well-being was manifest by the decrease in negative entries in the self-assessment scale.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004562:Electrocardiography; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy*; D008297:Male; D008879:Midodrine / Q000627:therapeutic use*; D005082:Physical Exertion; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*
D004983:Ethanolamines; D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; D008879:Midodrine
Untersuchungen mit dem Alpharezeptorenstimulator Gutron beim Orthostasesyndrom.